Professor of Pathology & Stephenson Chair in Cancer Translational Research, Stephenson Cancer Center, University of Oklahoma Health Sciences Center
United States
Joined February 2018
- Tweets16
- Following94
- Followers37
- Likes15
Jerry Wu retweeted
Research saves lives.
LUNGevity is proud to invest another $2 million in research to bring the next generation of breakthroughs to people affected by lung cancer.
These awards will support scientists working to detect lung cancer earlier, predict which treatments are most likely to work, overcome drug resistance, and make care more precise, durable, and accessible.
The expert-vetted projects also strengthen the research workforce and advance new strategies for treating RET-positive cancers and EGFR-positive lung cancer.
We are grateful to our donors and partners for supporting these strategic lung cancer research projects that keep the patient at the center of the work.
Learn more about this important research here: lungevity.org/blogs/lungevit…
@adib_elio — @MassGenBrigham
Tatiana Delgado Cruz, MD — @WeillCornell
@FrangiehChris — @ColumbiaMed
@BrendanHeiden — @washumedicine
@SurbhiSinghalMD — @UCD_Cancer
No Joon Song, PhD — @OSUCCC_James
@NehemiasGuevar5 — @SLU_Official
@TejasPatilMD — @CUCancerCenter
@ScientistJerry — @OUCollegeofMed @StephensonCC
@BobakParang — @OSUCCC_James
@LC_Initiative_ @RETpositive @ASTRO_org
Jerry Wu retweeted
RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion–Positive Breast Cancer and Beyond @CR_AACR @AACR aacrjournals.org/cancerres/a…
Jerry Wu retweeted
Out now! Simultaneous publication with #AACR23 poster—
Targeting RET solvent-front mutants with an alkynyl nicotinamide-based inhibitor, by Jie Wu et al.
aacrjournals.org/mct/article…
Jerry Wu retweeted
🥁🥁🥁Hot off the press. Thrilled to publish in Lancet Oncology👉 Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study🎯 #LCSM @JustinGainor @curijoey @GlopesMd @StephenVLiu @TheLancetOncol thelancet.com/journals/lanon…
A major difference in RET inhibition found between pralsetinib and selpercatinib cancercommunity.nature.com/p… #RETpositive
A major difference between pralsetinib and selpercatinib. See doi.org/10.1038/s41698-021-0…. #RET
Jerry Wu retweeted
+ NTRK fusion as mechanism of resistance to RET inhibitor👉🏼Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer @Annals_Oncology annalsofoncology.org/article…
Jerry Wu retweeted
As we look forward to a new year with more advances to come for patients with #cancer, we reflect on the many FDA approvals we saw in 2020. What field do you think had the most impactful additions to its armamentarium?
Check out our 2020 Recap here: targetedonc.com/view/experts…
42%Lung Cancers
18%Breast Cancers
36%Hematologic Malignancies
3%Gastrointestinal Cancers
33 votes • Final resultsStructural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations annalsofoncology.org/article…
nature.com/articles/s41598-0… Beneficial effects of low alcohol exposure, but adverse effects of high alcohol intake on glymphatic function
JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations nature.com/articles/srep0304…
Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the iJAK2/i gene in non-small cell lung cancer oncotarget.com/index.php?jou…
nature.com/articles/s41375-0… Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099